Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin.

Camptothecin (CPT) derivatives are presently in ongoing Phase I/II clinical trials. The interactions between 9-aminocamptothecin (9AC) and cisplatin (CDDP) have been studied in the IGROV-1 human ovarian cancer cell line used in the National Cancer Institute Drug Discovery Anticancer Screen. One-h simultaneous treatment with 9AC and CDDP produced synergistic cytotoxicity. Under these conditions, 9AC delayed the reversal of CDDP-induced DNA interstrand cross-links (ISCs) without modifying the maximum ISC frequency at 6 h after drug treatment. CDDP did not affect the amount and the kinetics of reversion of 9AC-induced DNA single-strand breaks. Simultaneous treatment with CDDP and 9AC prolonged the DNA synthesis inhibition produced by each drug alone. Consistently, flow cytometry analyses showed enhanced S-phase arrest in cells treated with the CDDP-9AC combination. The DNA polymerase inhibitor aphidicolin also increased the residual CDDP-induced ISCs. These results suggest that prolonged inhibition of DNA synthesis by CPTs potentiate the cytotoxicity of CDDP by inhibiting the reversal of CDDP-induced DNA damage. Therefore, the combination of CPTs and CDDP appears to be worthwhile in cancer chemotherapy.

[1]  Y. Pommier,et al.  Eukaryotic DNA topoisomerases I. , 1995, Biochimica et biophysica acta.

[2]  A. Sancar.  Mechanisms of DNA excision repair. , 1994, Science.

[3]  D. S. Hsu,et al.  Substrate spectrum of human excinuclease: repair of abasic sites, methylated bases, mismatches, and bulky adducts. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[4]  F. Zunino,et al.  Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types. , 1994, Anti-cancer drugs.

[5]  R. Motzer,et al.  Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. , 1994, Journal of the National Cancer Institute.

[6]  Y. Minagawa,et al.  Synergistic Enhancement of Cisplatin Cytotoxicity by SN‐38, an Active Metabolite of CPT‐11, for Cisplatin‐resistant HeLa Cells , 1994, Japanese journal of cancer research : Gann.

[7]  J. Yu,et al.  Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. , 1994, The Journal of clinical investigation.

[8]  M. Evans,et al.  Deficient gene specific repair of cisplatin-induced lesions in Xeroderma pigmentosum and Fanconi's anemia cell lines. , 1993, Carcinogenesis.

[9]  John Calvin Reed,et al.  Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. , 1993, Blood.

[10]  J. Alsner,et al.  Camptothecin inhibits both the cleavage and religation reactions of eukaryotic DNA topoisomerase I. , 1992, Journal of molecular biology.

[11]  T. Tatsumoto,et al.  Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line. , 1992, Cancer research.

[12]  N. Saijo,et al.  Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. , 1991, Cancer research.

[13]  C. Bendixen,et al.  Camptothecin-stabilized topoisomerase I-DNA adducts cause premature termination of transcription. , 1990, Biochemistry.

[14]  S. Chaney,et al.  Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. , 1990, Biochemistry.

[15]  L. Liu,et al.  DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. , 1989, Science.

[16]  Y. Pommier,et al.  Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. , 1989, Cancer research.

[17]  K. Kohn,et al.  Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. , 1989, Cancer research.

[18]  L. Liu,et al.  Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. , 1989, Cancer research.

[19]  R. Fisher,et al.  1-beta-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum(II) and modification of platinum-induced DNA interstrand cross-linking. , 1989, Cancer research.

[20]  A. Fojo,et al.  Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. , 1988, Cancer research.

[21]  D. Hamer,et al.  Overexpression of metallothionein confers resistance to anticancer drugs. , 1988, Science.

[22]  A. Eastman,et al.  Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). , 1988, Biochemistry.

[23]  E. Pettersen,et al.  Synergistic cell inactivation by cis-dichlorodiammineplatinum in combination with 1-propargyl-5-chloropyrimidin-2-one. , 1987, British Journal of Cancer.

[24]  J. Wilson,et al.  Interactions of cis-diamminedichloroplatinum(II) with 1-beta-D-arabinofuranosylcytosine in LoVo colon carcinoma cells. , 1987, Cancer research.

[25]  J. Wang.  Recent studies of DNA topoisomerases. , 1987, Biochimica et biophysica acta.

[26]  B. Teicher,et al.  Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). , 1987, Cancer research.

[27]  D. Priest,et al.  Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[28]  P. Hanawalt,et al.  Preferential DNA repair of an active gene in human cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. Hertzberg,et al.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.

[30]  P. Lohman,et al.  Formation and repair of DNA interstrand cross-links in relation to cytotoxicity and unscheduled DNA synthesis induced in control and mutant human cells treated with cis-diamminedichloroplatinum(II). , 1985, Cancer research.

[31]  K. Kohn,et al.  DNA cross-linking as an indicator of sensitivity and resistance of mouse L1210 leukemia to cis-diamminedichloroplatinum(II) and L-phenylalanine mustard. , 1981, Cancer research.

[32]  P. Hérait,et al.  Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  K. Kohn,et al.  Cellular Determinants of Sensitivity and Resistance to DNA Topoisomerase Inhibitors , 1994 .

[34]  S. Chatterjee,et al.  Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. , 1994, Oncology research.

[35]  L. Liu,et al.  DNA topoisomerases: essential enzymes and lethal targets. , 1994, Annual review of pharmacology and toxicology.

[36]  J. Champoux.  6 Mechanistic Aspects of Type-I Topoisomerases , 1990 .

[37]  S. Lippard,et al.  Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. , 1985, Biochimica et biophysica acta.

[38]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.